Spire Healthcare Group (LON:SPI) Rating Reiterated by JPMorgan Chase & Co.

Spire Healthcare Group (LON:SPI)‘s stock had its “overweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research note issued on Thursday, Marketbeat.com reports. They currently have a GBX 344 ($4.28) target price on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 39.84% from the stock’s current price.

Separately, Berenberg Bank increased their price target on shares of Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the company a “buy” rating in a report on Wednesday.

Spire Healthcare Group Stock Down 0.8 %

Spire Healthcare Group stock opened at GBX 246 ($3.06) on Thursday. The stock has a market cap of £994.16 million, a P/E ratio of 3,514.29, a P/E/G ratio of 1.06 and a beta of 0.99. The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37. Spire Healthcare Group has a twelve month low of GBX 204 ($2.54) and a twelve month high of GBX 321.71 ($4.00). The company’s 50-day moving average price is GBX 237.75 and its two-hundred day moving average price is GBX 229.11.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.